Ashland Inc. reported third-quarter fiscal 2025 sales of $463 million, a 15% decrease year-over-year, with portfolio optimization initiatives reducing sales by $53 million. The company recorded a net loss of $742 million, primarily due to a $706 million non-cash goodwill impairment charge, compared to a net income of $6 million in the prior year. Adjusted EBITDA was $113 million, down 19% year-over-year, with portfolio optimization impacting it by $13 million.
Organic volumes decreased by four percent, as anticipated growth did not materialize, particularly in Specialty Additives and Personal Care. Despite these headwinds, Life Sciences maintained pharma growth momentum, and the company sustained strong margins through cost savings and operational discipline. Ongoing Free Cash Flow was $108 million.
Ashland narrowed its full-year fiscal 2025 outlook, now expecting sales of approximately $1.825 billion to $1.850 billion and Adjusted EBITDA in the range of $400 million to $410 million. The revised guidance reflects a stable but subdued macroeconomic environment and continued caution across customer channels, with current assumptions weighted toward the lower end of the range.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.